Literature DB >> 21656144

Adhesion molecules affected by treatment of lung cancer cells with epidermal growth factor.

Fernando L A Fonseca1, Ligia A Azzalis, David Feder, Everson Nogoceke, Virginia B C Junqueira, Vitor E Valenti, Luiz Carlos de Abreu.   

Abstract

Lung cancer is one of the leading causes of death in the world. Some tumor events are attributed to an important group of molecules (cadherins and integrins). We evaluated the interactions of cell adhesion molecules in cell lines from lung cancer. Two lung cancer cell lines were nonmetastatic (H358 and H441) and two were metastatic (H1299 and H292). All cell lines were treated with epidermal growth factor (EGF), and Western blot analysis was performed to assess the interactions between these proteins. The bronchoalveolar cells H358 showed the three analyzed proteins: E-cadherin, β-catenin, and p120 catenin. The adenocarcinoma cells H441 did not present p120 catenin, and carcinoma cells did not show E-cadherin (H1299) or p120 catenin (H292). FAK (pTyr925) was dephosphorylated in adenocarcinoma cells H441, absent in carcinoma cells H1299, and upregulated in the other carcinoma cells H292. p130Cas showed no difference when the cell lines were treated with EGF for 30 min; it was absent in the metastatic carcinoma cells H1299. Paxillin was dephosphorylated in adenocarcinoma cells H441 and also absent in other metastatic carcinoma cells H292. Vinculin showed the same results, and talin was downregulated in adenocarcinoma cells H441 when the cells were treated with EGF. Rap1 was downregulated and PYK2 was upregulated in the same cell line. Our data help to comprehend the mechanism involved in cell migration to the blood and metastasis generation. In conclusion, the expression patterns of cell-cell adhesion were not affected by EGF treatment but it affected cell-extracellular matrix adhesion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656144     DOI: 10.1007/s00408-011-9300-9

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  23 in total

Review 1.  E-cadherin-catenin cell-cell adhesion complex and human cancer.

Authors:  B P Wijnhoven; W N Dinjens; M Pignatelli
Journal:  Br J Surg       Date:  2000-08       Impact factor: 6.939

Review 2.  Where next for gefitinib in patients with lung cancer?

Authors:  Fiona Blackhall; Malcolm Ranson; Nick Thatcher
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

3.  Characterization of the focal adhesion complex in human non-small cell lung cancer cell lines.

Authors:  Valérie Forest; Lydia Campos; Jean-Michel Vergnon; Jérome Cornillon; Denis Guyotat
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

Review 4.  Diagnostic imaging in metastatic lung disease.

Authors:  E Dinkel; A Mundinger; D Schopp; G Grosser; K H Hauenstein
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 5.  The management of lung cancer.

Authors:  S G Spiro
Journal:  Lung       Date:  1982       Impact factor: 2.584

6.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer.

Authors:  R M Bremnes; R Veve; E Gabrielson; F R Hirsch; A Baron; L Bemis; R M Gemmill; H A Drabkin; W A Franklin
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

7.  EGF receptor activity is essential for adhesion-induced stress fiber formation and cofilin phosphorylation.

Authors:  Nathaly Marcoux; Kristiina Vuori
Journal:  Cell Signal       Date:  2005-03-31       Impact factor: 4.315

8.  Expression of E-cadherin and lymph node metastasis in resected non-small-cell lung cancer.

Authors:  T Hirata; T Fukuse; H Naiki; H Wada
Journal:  Clin Lung Cancer       Date:  2001-11       Impact factor: 4.785

Review 9.  Chemoprevention of lung cancer.

Authors:  Jean-Charles Soria; Edward S Kim; Jérôme Fayette; Sylvie Lantuejoul; Eric Deutsch; Waun Ki Hong
Journal:  Lancet Oncol       Date:  2003-11       Impact factor: 41.316

Review 10.  Lung cancer: therapeutic modalities and cytoprotection.

Authors:  J H Schiller
Journal:  Lung       Date:  1998       Impact factor: 2.584

View more
  2 in total

1.  Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.

Authors:  Elena Galvani; Elisa Giovannetti; Francesca Saccani; Andrea Cavazzoni; Leticia G Leon; Henk Dekker; Roberta Alfieri; Caterina Carmi; Marco Mor; Andrea Ardizzoni; Pier Giorgio Petronini; Godefridus J Peters
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

2.  NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.

Authors:  Elena Galvani; Jing Sun; Leticia G Leon; Rocco Sciarrillo; Ravi S Narayan; Robert Tjin Tham Sjin; Kwangho Lee; Kadoaki Ohashi; Daniëlle A M Heideman; Roberta R Alfieri; Guus J Heynen; René Bernards; Egbert F Smit; William Pao; Godefridus J Peters; Elisa Giovannetti
Journal:  Oncotarget       Date:  2015-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.